坦桑尼亚姆万扎地区HIV治疗前耐药流行率研究
该研究在坦桑尼亚姆万扎的Bugando医疗中心连续纳入2013至2015年的成人门诊患者,分析235条HIV pol序列,发现总体治疗前耐药(PDR)流行率为4.7%(95%CI 2.6%-8.2%),传播性耐药(TDR)为6.0%(95%CI 3.6%-9.8%),PDR较2008-10年显著下降且低于WHO触发公共卫生反应的阈值。
要点
- 总体PDR为4.7%(95%CI 2.6%-8.2%),低于WHO阈值。
- 非启动者PDR为3.1%,ART启动者为5.8%。
- TDR为6.0%(95%CI 3.6%-9.8%)。
核心结论
- PDR流行率较2008-10年显著下降,且低于WHO定义的触发公共卫生反应的阈值。
- 需要国家和系统性的监测来为坦桑尼亚的公共卫生策略提供信息。
研究设计与样本
- 2013至2015年在坦桑尼亚姆万扎Bugando医疗中心连续纳入成人门诊患者,分为ART启动者和非启动者两组。
- 排除既往暴露于抗逆转录病毒药物(预防母婴传播除外),按WHO指南分析HIV pol序列。
- 共分析235条序列(138例ART启动者,97例非启动者)。
主要发现
- 总体PDR为4.7%(95%CI 2.6%-8.2%),非启动者为3.1%(95%CI 1.1%-8.7%),ART启动者为5.8%(95%CI 3.0%-11.0%)。
- NNRTI耐药为3.0%(95%CI 1.5%-6.0%),NRTI耐药为1.7%(95%CI 0.7%-4.3%)。
- 未观察到PI耐药。
- TDR为6.0%(95%CI 3.6%-9.8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a 2008-10 study, we found a pretreatment HIV drug resistance (PDR) prevalence of 18.2% in patients at Bugando Medical Centre (BMC) in Mwanza, Tanzania. OBJECTIVES: To determine the prevalence of PDR and transmitted HIV drug resistance (TDR) in patients visiting the BMC from 2013 to 2015. METHODS: Adult outpatients were sequentially enrolled into two groups, separated by whether they were initiating ART. Previous exposure to antiretroviral drugs, except for prevention of mother-to-child transmission, was an exclusion criterion. HIV pol sequences were analysed according to WHO guidelines for surveillance of PDR and TDR. RESULTS: Two hundred and thirty-five sequences were analysed (138 ART initiators, 97 non-initiators). The prevalence of PDR was 4.7% (95% CI 2.6%-8.2%) overall, 3.1% (95% CI 1.1%-8.7%) for non-initiators and 5.8% (95% CI 3.0%-11.0%) for ART initiators. PDR to NNRTIs and nucleoside or nucelotide reverse transcriptase inhibitors was found in 3.0% (95% CI 1.5%-6.0%) and 1.7% (95% CI 0.7%-4.3%) of patients, respectively. Resistance to PIs was not observed. The prevalence of TDR was 6.0% (95% CI 3.6%-9.8%). CONCLUSIONS: Prevalence of PDR significantly decreased compared with 2008-10 and was below the WHO-defined threshold for triggering a public health response. National and systematic surveillance is needed to inform Tanzania's public health strategy.
引用
- Rudovick L, Brauner JM, Englert J, et al. Prevalence of pretreatment HIV drug resistance in Mwanza, Tanzania. J Antimicrob Chemother. 2018. PMID: 30165451. doi:10.1093/jac/dky332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。